View Document Preview and Link Document Date: 2013-12-10 10:20:22 Open Document File Size: 702,63 KB Share Result on Facebook
City Montreal / / Company Bristol-Myers Squibb Canada / Bristol-Myers Squibb Company / Ames / HBV / / Country Canada / / Event M&A / FDA Phase / / IndustryTerm HIV treatment / hepatitis B therapy / treatment for HIV / / MedicalCondition rare hereditary problems / HIV infection / Tumor / lung adenomas / HIV / tumors / liver adenomas / headache / previously demonstrated hypersensitivity / Hematuria / Carcinogenesis / Hyperglycemia / nausea / compensated liver disease / hepatitis B / benign vascular tumors / viremia / microglial tumors / Lapp lactase deficiency / Vomiting / liver carcinomas / lung carcinomas / fatigue / Lactic acidosis / virus infection / histologically active disease / Diarrhea / Skin fibromas / infection / hepatitis / dizziness / carcinomas / liver disease / chronic hepatitis B / mouse lymphoma cells / lung tumor / / MedicalTreatment continuous ambulatory peritoneal dialysis / hemodialysis / highly active antiretroviral therapy / Liver Transplant / HAART / CAPD / / OperatingSystem L3 / / Organization DOSAGE AND ADMINISTRATION / / / Position General / / Product PROPER USE OF THIS MEDICATION / Strength Clinically Relevant Nonmedicinal Ingredients Tablets / cyclosporine / INTERACTIONS WITH THIS MEDICATION / lamivudine / ABOUT THIS MEDICATION / General BARACLUDE / BARACLUDE / / Technology Geriatrics / pharmacokinetics / dialysis / / SocialTag 
PID comments (clarifax in January 2006)